What is the long-term trend for Esperion Therapeutics's research and development expense?

Over 4 years (2021 to 2025), Esperion Therapeutics's research and development expense has grown at a -18.0% compound annual growth rate (CAGR), from $105.98M to $47.85M.

Esperion Therapeutics ESPR Research and development expense

Research and development expense at other companies

AmgenAMGN

——

Zevra Therapeutics, Inc.ZVRA

——

OrganonOGN

——

ViatrisVTRS

——

Avalo TherapeuticsAVTX

——

AnaptysBio, Inc.ANAB

——

Other financials

Income statement

See full

Revenue$80.1M+23.2%

Operating income-$6.6M+70.2%

Net income-$25.2M+37.7%

EPS (diluted)-$0.10+52.4%

Balance sheet

See full

Cash & equivalents$156.2M+36.2%

Total debt$155.2M+6.1%

Total equity-$307.9M+27.8%

Total assets$462.5M+42.7%

Cash flow

See full

Operating cash flow-$27.7M-22.5%

CapEx$189.0K—

Free cash flow-$27.9M-23.3%

Valuation

See full

Market cap$811.73M+283%

Enterprise value$810.81M+233%

P/S1.9×+1.1×

Profitability

See full

Operating margin18.1%+12.7pp

Net margin-34.8%+8.0pp

FCF margin-30.7%—

Returns & leverage

See full

Return on equity-260.8%—

Debt / equity0.8×—

Current ratio1.5×+0.4×

Where this comes from

Reported directly by Esperion Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Esperion Therapeutics's research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Esperion Therapeutics's research and development expense?: Esperion Therapeutics (ESPR) reported research and development expense of $8.99M in Q1 2026.
How has Esperion Therapeutics's research and development expense changed year-over-year?: Esperion Therapeutics's research and development expense decreased by 28.4% year-over-year, from $12.56M to $8.99M.
What is the long-term trend for Esperion Therapeutics's research and development expense?: Over 4 years (2021 to 2025), Esperion Therapeutics's research and development expense has grown at a -18.0% compound annual growth rate (CAGR), from $105.98M to $47.85M.